Raesa Yolanda, Raesa
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Potensi Suplementasi Resveratrol dalam Mengatasi Efek Negatif Hormon Tiroid pada Terapi Obesitas: Uji Preklinik Ruslami, Rovina; Rosalita, Renny; Yolanda, Raesa; Agustin, Agnes; Sudigdoadi, -
Majalah Kedokteran Bandung Vol 48, No 1 (2016)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (428.017 KB)

Abstract

Terapi obesitas menggunakan hormon tiroid menurunkan berat badan dengan nyata, namun menyebabkan berbagai efek negatif seperti stres oksidatif, kerusakan DNA, dan muscle wasting. Penelitian ini bertujuan mengkesplorasi potensi resveratrol (RSV), polifenol alami yang mempunyai efek antioksidan, anti-inflamasi, dan antiobesitas. Uji preklinik dengan rancangan acak sederhana dilakukan di Lab Hewan Fakultas Kedokteran Universitas Padjadjaran menggunakan 40 ekor tikus Wistar yang diinduksi obesitas. Hewan model obesitas dialokasikan secara acak ke dalam dua kelompok selama periode Agustus–November 2014. Kelompok perlakuan mendapat hormon tiroid 3 (HT3) dan RSV, serta kelompok kontrol mendapat HT3 saja selama 14 hari. Hewan coba yang mendapat HT3 dan RSV memiliki bobot badan lebih besar (290,5 g vs 251 g, p=0,016), massa otot lebih berat (2,57 g vs 2,25 g, p=0,036), indeks adiposit lebih kecil (0,89% vs 1,02%, p=0,026), dan area under the curve (AUC) gukosa lebih kecil (1.849,2 mg.mnt/dL vs 2.591,7 mg.mnt/dL, p<0,001) dibanding yang mendapat HT3 saja. Tidak terdapat perbedaan kadar MDA plasma (0,49 nmol/mL vs 0,44 nmol/mL, p=0,430) dan kerusakan DNA (19,7 pixel vs 22,0 pixel, p=0,657) pada kedua kelompok yang mungkin berhubungan dengan dosis dan lama pemberian resveratrol. Suplementasi resveratrol berpotensi mengatasi efek negatif hormon tiroid pada hewan model obesitas. Perlu penelitian lanjutan untuk mengetahui dosis optimal resveratrol sebagai antioksidan pada pengobatan obesitas menggunakan hormon tiroid. [MKB. 2016;48(1):51–7]Kata kunci: Hormon tiroid, obesitas, resveratrol, uji preklinikResveratrol Supplementation Potential in Managing Negative Effects of Thyroid Hormone during Obesity Treatment: a Pre-Clinical TrialAbstractTreatment of obesity using thyroid hormone could give significant result in decreasing body weight, but it also causes various negative effects such as oxidative stress, DNA damage, and muscle wasting. This sudy aimed to explore the potential of resveratrol, a natural polyphenol, that has anti-oxidant, anti-inflammatory, and anti-obesity effects, in managing negative effects of thyroid hormone used as anti-obesity. A preclinical trial was conducted at the animal laboratory, Faculty of Medicine, Universitas Padjadjaran. Forty male Wistar rats underwent obesity induction before randomly allocated into intervention and control groups in August–November 2014. The intervention group received a 14-days of triiodothyronine (T3) and resveratrol (RSV), while the control group received T3 only. Obese rats treated with T3 and RSV were heavier (body weight of 290.5 g vs 251.0 g, p<0.016), had a heavier muscle mass (2.57 g vs 2.25 g, p=0.036), smaller adipocyte index, (0.89% vs 1.02%, p=0.026) and smaller glucose area under the curve (AUC) (1,848.2 mg.mnt/dL vs 2,591.7 mg.mnt/dL, p<0.001) than those who were treated with T3 only. There was no significance difference in MDA plasma levels (0.49 nmol/mL vs 0.44 nmol/mL, p=0.0430) and DNA damage (19.7 pixel vs 22.0 pixel, p=0.657) between groups, probably due to insufficient dosage of resveratrol. Our results indicate that resveratrol supplementation could counter negative effects of thyroid hormone used as anti-obesity in obese-rats model treated with T3. More research is needed to determine the adequate dosage of resveratrol to elicit anti-oxidant effect that could minimize the negative effects of thyroid hormone as anti-obesity. [MKB. 2016;48(1):51–7]Key words: Obesity, preclinical trial, resveratrol, thyroid hormone DOI: 10.15395/mkb.v48n1.734
Drug-induced hypersensitivity syndrome with liver injury due to phenytoin: A case report Wijaya, Lorettha; Adevita, Stella; Alvianto, Steven; Christiani, Yoseveline; Cahyadi, Alius; Yolanda, Raesa
Journal of General - Procedural Dermatology & Venereology Indonesia Vol. 8, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Drug-induced hypersensitivity syndrome (DIHS) is a rare and severe systemic drug reaction characterized by skin involvement, internal organ complications, and hematologic disorders. Management of this condition is challenging due to its wide range of cutaneous manifestations and 10% mortality rate. Case Illustration: A 52-year-old male presented with widespread redness throughout his body with a prior history of regular phenytoin consumption. The rash continued to spread despite the patient’s abrupt discontinuation of the suspected medication. He was diagnosed with atypical DIHS according to J-SCAR criteria and was given high-dose corticosteroid. Drastic clinical improvement was observed after nine days of therapy, and complete resolution of the rash was achieved after 14 days. The steroid was stopped after four weeks, and no relapse was observed after four months of follow-up. Discussion: Discontinuing the suspected medication is the first crucial step in DIHS management. No specific pharmaceutical strategy has been established for this syndrome; however, systemic corticosteroids have been frequently prescribed as a first-line therapy. Steroids need to be tapered off slowly over 6–8 weeks, even upon clinical resolution, to prevent relapse. In the current case, the steroid was tapered off slowly over four weeks. The lack of relapse observed after steroid discontinuation could be due to the fact that the patient stopped consuming the suspected medication immediately. Conclusion: Education on the consequences of prescribing high-risk medications is important. Early detection and prompt cessation of offending medications are needed for better DIHS outcomes.